PubMed COVID-19 Clinical Care

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

Sunday, February 25, 2024 - 4:00 AM

CONCLUSIONS: AZD7442 reduced the risk of progression to severe COVID-19, hospitalization, and death, was well tolerated through 15 months, and exhibited predictable pharmacokinetics in outpatients with mild-to-moderate COVID-19. These data support

Neurosurgery to Overcome the Living with COVID-19 Era

Sunday, February 25, 2024 - 4:00 AM

No abstract

Pediatric Patients During COVID-19 - Part 1 - Pediatric Trauma, What Have We Learned?

Sunday, February 25, 2024 - 4:00 AM

CONCLUSION AND RELEVANCE: During C-19, there was a higher rate of pediatric injuries compared to Pre-C-19. The incidence of domestic oral and maxillofacial injuries increased despite the considered home safety.

Global insight into the occurrence, treatment technologies and ecological risk of emerging contaminants in sanitary sewers: Effects of the SARS-CoV-2 coronavirus pandemic

Sunday, February 25, 2024 - 4:00 AM

The SARS-CoV-2 pandemic caused changes in the consumption of prescribed/non-prescribed drugs and the population's habits, influencing the detection and concentration of emerging contaminants (ECs) in sanitary sewage and harming environmental and

Evaluation of size-exclusion chromatography, multi-angle light scattering detection and mass photometry for the characterization of mRNA

Sunday, February 25, 2024 - 4:00 AM

The recent approval of messenger ribonucleic acid (mRNA) as vaccine to combat the COVID-19 pandemic has been a scientific turning point. Today, the applicability of mRNA is being demonstrated beyond infectious diseases, for example in cancer

The incidence and impact of atrial fibrillation on hospitalized Coronavirus disease-2019 patients

Sunday, February 25, 2024 - 4:00 AM

CONCLUSION: AF is common in patients hospitalized for COVID-19, and is associated with poorer in-hospital mortality, immediate complications and increased healthcare resource utilization.

Perception of interpersonal distance and social distancing before and during COVID-19 pandemic

Sunday, February 25, 2024 - 4:00 AM

Since COVID-19 is easily transmitted among people in close physical proximity, the focus of epidemiological policy during the COVID-19 crisis included major restrictions on interpersonal distance. However, the way in which distance restrictions

Pipette-free field-deployable molecular diagnostic kit for bimodal visual detection of infectious RNA viruses

Sunday, February 25, 2024 - 4:00 AM

Here, we developed a field-deployable molecular diagnostic kit for the detection of RNA viruses that operates in a pipette-free manner. The kit is composed of acrylic sticks, PCR tubes, and palm-sized three-dimensional(3D)-printed heaters operated by

PASS to End TB in Europe: Accelerated efforts on Prevention and Systematic Screening to End Tuberculosis in the WHO European Region by 2030

Sunday, February 25, 2024 - 4:00 AM

INTRODUCTION: The World Health Organization (WHO) estimated that in 2022, 10.6 million people developed tuberculosis (TB). Over 400 000 TB cases were rifampicin or multidrug-resistant TB. The 7.5 million TB notifications in 2022 were the highest ever

The use of interpreter services and its barriers faced by hospital staff when accessing interpreters for patients with low English proficiency during the COVID-19 pandemic

Sunday, February 25, 2024 - 4:00 AM

CONCLUSION: Some systemic barriers including an inflexible booking process and long wait times for immediate interpreter services were identified. The low use of interpreter services is attributed to the difficulties accessing the service and poor